インターナショナル

NKGen and HekaBio team up on NK Cell therapy in Japan

NKGen Biotech, Inc. is a clinical-stage biotech firm. They focus on NK cell therapies, both autologous and allogeneic. Now, they've teamed up with Tokyo's HekaBio K.K. This partnership will help develop and market NKGen's autologous NK cell therapy, troculeucel, in Japan. The collaboration follows HekaBio’s recent investment in NKGen through common equity. HekaBio will lead clinical development in Japan. They will also handle regulatory talks with the Pharmaceuticals and Medical Devices Agency (PMDA). Their goal is to get pre-market approval for troculeucel for several neurodegenerative diseases, like Alzheimer’s and Parkinson’s. Troculuecel is an autologous, non-genetically modified cell therapy. This means it can use Japan’s expedited approval pathway for regenerative medicine. As a result, patients can access it much faster than in other major global markets. HekaBio plans to use this…